The Prevalence of HIV Drug Resistance among Treatment-failure Individuals and Treatment-na?ve Indivi

• 作 者: WU Jing NORRIS Jessie LIU Hui Xin LI Zheng SU Ying Ying ZHU Lin WANG Ning
• 机 构: National Center for AIDS/STD Control and Prevention,China Center for Disease and Prevention,School o
• 出 处: Biomedical and Environmental Sciences
• 发表日期: 2014年11期
• 关键词: HIV Drug resistance Meta-analysis China

Objective To understand drug resistance prevalence among treatment-failure and treatment-nave HIV-positive individuals in China.Methods We searched five electronic databases(Wanfang,CNKI,CQVIP,SinoMed,and Pubmed) for studies of HIV drug resistance.Random-effects models were carried out to estimate the prevalence of drug resistance among treatment-failure and treatment-nave individuals,respectively.Results The estimated nationwide rates of HIV drug resistance to any-class drugs among treatment-failure and treatment-nave individuals were 57%(95% CI:49%-65%) and 3.23%(95% CI:2.47%-4.07%),respectively.Among the drug classes,the prevalence of resistance to PIs was low(1.45%;95% CI:0.73%-2.33%) in treatment-failure individuals,although high rates of resistance to NNRTIs(54%;95% CI:45%-63%) and NRTIs(40%;95% CI:32%-49%) were found.Resistance to any-class drugs,NNRTIs and NRTIs manifested regional differences,but resistance to PIs did not.Positive correlations were observed between resistance to NNRTIs and NRTIs among treatment-failure and treatment-nave individuals,respectively.Conclusion The prevalence of HIV drug resistance to NNRTIs and NRTIs among treatment-failure individuals was high.In contrast,the prevalence of drug resistance among treatment-nave individuals was low.The epidemics of drug resistance matched current treatment strategies and interventions in China.Surveillance for HIV drug resistance is necessary to assess the sustainability and durability of current treatment regimens.

Objective To understand drug resistance prevalence among treatment-failure and treatment-nave HIV-positive individuals in China. Methods We searched five electronic databases (Wanfang, CNKI, CQVIP, SinoMed, and Pubmed) for studies of HIV drug resistance. Random- effects models were carried out to estimate the prevalence of drug resistance among treatment-failure and treatment-nave individuals, respectively. Results The estimated nationwide rates of HIV drug resistance to any-class drugs among treatment-failure and treatment-nave (95% CI: 49% -65%) and 3.23% (95% CI: 2.47% -4.07%), respectively. Amd the drug classes, the prevalence of resistance to PIs was low (1.45%; 95 % CI: 0.73% -2.33%) in treatment-failure individuals, although high rates of resistance to NNRTIs (54%; 95% CI: 45% -63%) and NRTIs %) were found. Resistance to any-class drugs, NNRTIs and NRTIs manifested regional differences, but resistance to PIs did not. Positive correlations were observed between re sistance to NNRTIs and NRTIs among treatment-failure and treatment-nave individuals, respectively. Conclusions The prevalence of HIV drug resistance to NNRTIs and NRTIs among treatment-failure individuals was high. contrast, the prevalence of drug resistance among treatment-na ve individuals was low. Epidemics of drug resistance matched current treatment strategies and interventions in China. Surveillance for HIV drug resistance is necessary to assess the sustainability and durability of current treatment regimens.